Article, News
Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation at the 5th World Congress…
Article, Media, News
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Article, Media, News
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted that PTX is on the…
Article, News
Prescient Therapeutics secures speculative buy recommendation from Bioshares
Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company released positive trial results from its Phase Ib study in…
Article, News
Prescient to advance PTX-100 to phase II for refractory T-cell lymphomas
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…
Article, News
Prescient Reveals PTX-100 Phase 1b Study Results in T-Cell Lymphoma
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…
Article, News
Phase 1b study of Prescient Therapeutics’ (ASX: PTX) PTX-100 shows excellent safety and promising efficacy in TCL patients
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased at the annual meeting of the American Society of Hematology (ASH) in…
Article, News
Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M
In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt of AU$2.4 million as R&D Tax Incentive rebate for the…
Article, News
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter
Article, News
MoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunity
Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a valuation range of 11.6c (bear case) to 16.3c per share (bull case)….